William Heppenstall
Internal Medicine · Philadelphia, PANPI 1023558400
Payments from drug & device makers
Across 497 payments — averaging $25.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- AbbVie$2K
- Novo Nordisk$1K
- GSK$744
- Pfizer$685
- Esperion Therapeutics, Inc.$683
- plus $5K from 31 others
What the payments were for
- Food & beverage$12,05197%
- Education$4223%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 48 | $2,437 |
| AbbVie | 90 | $1,879 |
| Novo Nordisk | 45 | $1,077 |
| GSK | 33 | $744 |
| Pfizer | 37 | $685 |
| Esperion Therapeutics, Inc. | 18 | $683 |
| Lilly USA, LLC | 27 | $676 |
| Boehringer Ingelheim | 25 | $612 |
| Bayer | 25 | $445 |
| Amgen | 18 | $334 |
| Astellas Pharma US Inc | 7 | $312 |
| Novartis | 17 | $291 |
| Daiichi Sankyo Inc. | 8 | $284 |
| Otsuka America Pharmaceutical, Inc. | 13 | $257 |
| Ironwood Pharmaceuticals, Inc | 9 | $193 |
| Sumitomo Pharma America, Inc. | 13 | $191 |
| Johnson & Johnson | 9 | $180 |
| Exact Sciences | 7 | $162 |
| Xeris Pharmaceuticals, Inc. | 7 | $162 |
| E.r. Squibb & Sons, L.L.C. | 2 | $112 |
| Global Blood Therapeutics, Inc. | 6 | $92 |
| Merck | 5 | $88 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $80 |
| Dexcom, Inc. | 3 | $61 |
| Idorsia Pharmaceuticals US Inc | 3 | $59 |
| Ardelyx, Inc. | 2 | $54 |
| Axsome Therapeutics, Inc. | 2 | $53 |
| Kowa Pharmaceuticals America, Inc. | 3 | $49 |
| Verona Pharma, Inc. | 2 | $49 |
| Azurity Pharmaceuticals, Inc. | 2 | $31 |
| Insulet Corporation | 1 | $27 |
| Lundbeck LLC | 1 | $27 |
| Gilead | 1 | $22 |
| Abbott | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Theracosbio, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,473 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 362 | $349,478 |
| JardianceEmpagliflozin | 300 | $308,142 |
| TrulicityDulaglutide | 242 | $275,250 |
| EliquisApixaban | 252 | $272,122 |
| OzempicSemaglutide | 215 | $226,898 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 284 | $200,927 |
| JanuviaSitagliptin Phosphate | 155 | $168,856 |
| LinzessLinaclotide | 199 | $154,410 |
| XareltoRivaroxaban | 105 | $118,387 |
| RybelsusSemaglutide | 49 | $70,856 |
| VraylarCariprazine Hcl | 35 | $53,221 |
| Breo ElliptaFluticasone/Vilanterol | 91 | $42,734 |
| EntrestoSacubitril/Valsartan | 28 | $41,565 |
| MounjaroTirzepatide | 38 | $39,451 |
| Varenicline Tartrate | 135 | $36,372 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta | $2,437 | $385,702419 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $612 | $335,628343 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $676 | $314,701280 claims |
| Novo NordiskOzempic, Rybelsus | $1,077 | $297,754264 claims |
| PfizerEliquis, Nurtec Odt | $685 | $291,133266 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $744 | $258,021406 claims |
| AbbVieLinzess, Vraylar, Restasis, Ubrelvy | $1,879 | $246,682278 claims |
| MerckJanuvia | $88 | $168,856155 claims |
| Johnson & JohnsonXarelto, Invokana | $180 | $140,892135 claims |
| NovartisEntresto | $291 | $41,56528 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $191 | $21,39926 claims |
| Astellas Pharma US IncMyrbetriq | $312 | $19,71627 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.
Other internal medicine in Philadelphia
- Jonathan EpsteinPhiladelphia$13.1M
- Pitamber DevgonPhiladelphia$7.5M
- Walter KraftPhiladelphia$3.7M
- Daniel RaderPhiladelphia$3.3M
- Archna BajajPhiladelphia$2.9M
- Gary YeomanPhiladelphia$2.4M
- Melina MarmarelisPhiladelphia$2.1M
- Adam WaxmanPhiladelphia$894K
- Donna GavaronePhiladelphia$728K
- Eyob FeyssaPhiladelphia$693K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.